Bioventus
BVS
151 hedge funds and large institutions have $478M invested in Bioventus in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 46 increasing their positions, 51 reducing their positions, and 20 closing their positions.
249% more call options, than puts
Call options by funds: $2.71M | Put options by funds: $775K
80% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 20
9% more funds holding
Funds holding: 138 → 151 (+13)
0.68% more ownership
Funds ownership: 68.94% → 69.62% (+0.68%)
10% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 51
11% less capital invested
Capital invested by funds: $537M → $478M (-$59.3M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.49M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.59M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.67M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.34M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.32M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$4.17M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.83M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.83M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.64M |
BVS Hedge Fund Activity: Q4 2024 in Review
151 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q4 2024, worth a combined $478M — down 11% from $537M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BVS positions and 20 closed out — a net gain of 16 holders — while 46 added to existing stakes and 51 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $9.49M. The largest seller was Morgan Stanley, cutting an estimated $4.32M.
- 151 institutional investors held Bioventus (BVS) as of Q4 2024, up from 138 in Q3 2024.
- Funds reported $478M of Bioventus stock for Q4 2024, down 11% quarter-over-quarter.
- 36 funds opened new Bioventus positions in Q4 2024 and 20 closed out, a net change of +16 holders.
- The largest Bioventus buyer in Q4 2024 was Fidelity Investments, an estimated $9.49M added.
- The largest Bioventus seller in Q4 2024 was Morgan Stanley, an estimated $4.32M sold.
Based on aggregated 13F filings for Q4 2024.